Your browser doesn't support javascript.
Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky.
Hamorsky, Krystal T; Bushau-Sprinkle, Adrienne M; Kitterman, Kathleen; Corman, Julia M; DeMarco, Jennifer; Keith, Rachel J; Bhatnagar, Aruni; Fuqua, Joshua L; Lasnik, Amanda; Joh, Joongho; Chung, Donghoon; Klein, Jon; Flynn, Joseph; Gardner, Marti; Barve, Shirish; Ghare, Smita S; Palmer, Kenneth E.
  • Hamorsky KT; James Graham Brown Cancer Center, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA. Krystal.hamorsky@louisville.edu.
  • Bushau-Sprinkle AM; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA. Krystal.hamorsky@louisville.edu.
  • Kitterman K; Department of Medicine, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA. Krystal.hamorsky@louisville.edu.
  • Corman JM; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • DeMarco J; Department of Medicine, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Keith RJ; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Bhatnagar A; Department of Medicine, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Fuqua JL; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Lasnik A; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Joh J; Department of Microbiology and Immunology, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Chung D; Christine Lee Brown Envirome Institute, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Klein J; Diabetes and Obesity Center, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Flynn J; Christine Lee Brown Envirome Institute, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Gardner M; Diabetes and Obesity Center, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Barve S; James Graham Brown Cancer Center, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Ghare SS; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
  • Palmer KE; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, University of Louisville, Louisville, KY, USA.
Sci Rep ; 11(1): 18285, 2021 09 14.
Article in English | MEDLINE | ID: covidwho-1410888
ABSTRACT
Serological assays intended for diagnosis, sero-epidemiologic assessment, and measurement of protective antibody titers upon infection or vaccination are essential for managing the SARS-CoV-2 pandemic. Serological assays measuring the antibody responses against SARS-CoV-2 antigens are readily available. However, some lack appropriate characteristics to accurately measure SARS-CoV-2 antibodies titers and neutralization. We developed an Enzyme-linked Immunosorbent Assay (ELISA) methods for measuring IgG, IgA, and IgM responses to SARS-CoV-2, Spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins. Performance characteristics of sensitivity and specificity have been defined. ELISA results show positive correlation with microneutralization and Plaque Reduction Neutralization assays with infectious SARS-CoV-2. Our ELISA was used to screen healthcare workers in Louisville, KY during the first wave of the local pandemic in the months of May and July 2020. We found a seropositive rate of approximately 1.4% and 2.3%, respectively. Our analyses demonstrate a broad immune response among individuals and suggest some non-RBD specific S IgG and IgA antibodies neutralize SARS-CoV-2.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Language: English Journal: Sci Rep Clinical aspect: Diagnosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic study Language: English Journal: Sci Rep Clinical aspect: Diagnosis Year: 2021
...